Organon

Organon Completes Acquisition of Forendo Pharma

Retrieved on: 
月曜日, 12月 13, 2021
Health, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Forward-looking statement, U.S. Securities and Exchange Commission, Security (finance), Lead, Company, Physician, Patent, NYSE, Private Securities Litigation Reform Act, MRK, Industry, Woman, Seed, COVID-19, Acquisition, Research and development, HSD17B1, SEC, Chronic liver disease, Endometriosis, Moelis & Company, Novartis, OGN, Tissue, Achievement, Prevalence, Investment, Anovulation, Intracrine, Form 10-K, HSD17B, PCOS, News, Health, Pharmaceutical industry, Risk management, Merck, Organon, Organon, Forendo, ORGANON, FORENDO

Organon (NYSE: OGN), a global womens healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in womens health.

Key Points: 
  • Organon (NYSE: OGN), a global womens healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in womens health.
  • Here for her health, Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas.
  • These statements include statements about the acquisition of Forendo and the potential for innovation and future treatment options.
  • Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Organon to Acquire Forendo Pharma

Retrieved on: 
木曜日, 11月 11, 2021
Baby, Maternity, Pharmaceutical, Health, Consumer, MSD, Achievement, Science, Private Securities Litigation Reform Act, News, Intracrine, Tissue, Novartis, Health, OGN, Endometriosis, PCOS, Disease, Patent, CEO, Security (finance), Failure, Seed, MRK, Investment, Infertility, COVID-19, Multimedia, Lists of diseases, Forward-looking statement, Lead, Woman, Acquisition, Chronic liver disease, U.S. Securities and Exchange Commission, Hyperandrogenism, SEC, NYSE, HSD17B, Review, Hart–Scott–Rodino Antitrust Improvements Act, Physician, HSD17B1, Anovulation, Abdominal pain, Patient, Risk, Form 10-K, Pharmaceutical industry, Risk management, Organon, Forendo, ORGANON, FORENDO

Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in womens health.

Key Points: 
  • Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in womens health.
  • Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach.
  • Our acquisition of Forendo further demonstrates our commitment to building a pipeline of impactful treatment options for women with unmet medical needs.
  • In addition to womens health programs, Forendo has a strategic collaboration with Novartis leveraging its unique HSD17B platform in chronic liver diseases.

InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board

Retrieved on: 
火曜日, 10月 12, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Company, Tumor microenvironment, Supervisory board, B cell, Doctor of Philosophy, Theca interna, CD8, Phase, Technology, Survival, Merck, Ipilimumab, Cancer, Schering-Plough, Apoptosis, PTEN, Melanoma, FDA, Metastasis, ICD, University, MicroRNA, Organon, Induced cell cycle arrest, Immune system, Mirna, Berkeley, Third Rock Ventures, Knowledge, Disease, CEO, Therapy, Acquisition, Patient, Immunity, Pharmaceutical industry, Vaccine, INT-1B3, InteRNA Technologies, INT-1B3, INTERNA TECHNOLOGIES

InteRNA Technologies , a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member of the Companys Supervisory Board.

Key Points: 
  • InteRNA Technologies , a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member of the Companys Supervisory Board.
  • Dr. van Elsas transitions from the Companys Scientific Advisory Board where he served as a member since February 2019.
  • He will succeed Mark Vaeck, PhD, who has stepped down from his position on the Supervisory Board.
  • Over the past two years, it has been great to see how Roel and his team advanced the first lead candidate, INT-1B3, from preclinical proof-of-concept to its clinical evaluation, added Dr. Andrea van Elsas, member of InteRNAs Supervisory Board.

Organon Receives FDA Clearance for Technological Updates to the Jada® System, a Medical Device Intended to Control Postpartum Hemorrhage

Retrieved on: 
月曜日, 10月 11, 2021
Medical Supplies, Health, FDA, Medical Devices, Consumer, Hospitals, Baby, Maternity, MSD, Internal bleeding, Forward-looking statement, Incidence, Patent, Veni, vidi, vici, Contraindication, Vacuum, Bleeding, COVID-19, Food, Use, United States National Library of Medicine, JADA, Form 10-K, SEC, Investment, FDA, MRK, News, Health, Safety, U.S. Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Woman, Security (finance), Uterine atony, Effectiveness, NYSE, Acquisition, Oxytocin, OGN, Food delivery, Uterus, Medical device, Risk management, Birth control, Pharmaceutical industry, the Jada, Organon, THE JADA, ORGANON

Postpartum hemorrhage continues to be one of the most common complications of childbirth and this recent FDA clearance supports our ability to continue providing healthcare providers this important option for treating women with abnormal postpartum bleeding.

Key Points: 
  • Postpartum hemorrhage continues to be one of the most common complications of childbirth and this recent FDA clearance supports our ability to continue providing healthcare providers this important option for treating women with abnormal postpartum bleeding.
  • Organon estimates this updated version of the Jada System should be available to customers in the United States in January 2022.
  • JADA is designed to apply low level vacuum to encourage normal contraction of the uterus to provide control and treatment of abnormal uterine bleeding or hemorrhage after childbirth.
  • Please refer to the Jada System Instructions for Use for indications, warnings, precautions, and contraindications at tinyurl.com/JADAIFU2 .

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

Retrieved on: 
火曜日, 7月 27, 2021
Health, Consumer, Women, Baby, Maternity, Pharmaceutical, Biotechnology, Preterm birth, Prostaglandin, Ebopiprant, ObsEva, Organon, EBOPIPRANT, OBSEVA, ORGANON

Ebopiprant is an investigational, orally active, selective prostaglandin F2 (PGF2) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions.

Key Points: 
  • Ebopiprant is an investigational, orally active, selective prostaglandin F2 (PGF2) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions.
  • Brian OCallaghan, CEO of ObsEva, commented, "Organon is the ideal partner for the development and commercialization of ebopiprant and we see this agreement as an important step in advancing this investigational agent.
  • Under the terms of the agreement, Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant.
  • In November 2020, ObsEva announced positive results from PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of ebopiprant in preterm labor.

Merck Declares Record Date and Dividend for the Organon & Co. Spinoff

Retrieved on: 
金曜日, 5月 7, 2021
Biotechnology, General Health, Pharmaceutical, Health, Dividends, Special dividend, MRK, Financial market, Schering-Plough, Merck & Co., Merck, Organon, MERCK, ORGANON

This spinoff will position Organon as a successful, independent, publicly traded company with a compelling portfolio of important medicines, particularly in women\xe2\x80\x99s health,\xe2\x80\x9d said Rob Davis, president, Merck.

Key Points: 
  • This spinoff will position Organon as a successful, independent, publicly traded company with a compelling portfolio of important medicines, particularly in women\xe2\x80\x99s health,\xe2\x80\x9d said Rob Davis, president, Merck.
  • Merck expects the special dividend of Organon stock will be distributed on June 2, 2021.\nThere is no current market for Organon common stock.
  • "When issued" trading of Organon common stock will continue until Merck pays the special dividend distribution of Organon common stock on June 2, 2021.
  • Merck shares trading under "MRK" will carry the right to receive shares of Organon through the special dividend distribution.

Merck to Hold Investor Briefing Featuring Organon on May 3

Retrieved on: 
火曜日, 4月 27, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Organon, Merck, ORGANON, MERCK

It will have a portfolio of more than 60 established medicines that address an entire spectrum of conditions women face and other medical needs.

Key Points: 
  • It will have a portfolio of more than 60 established medicines that address an entire spectrum of conditions women face and other medical needs.
  • We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.
  • These statements are based upon the current beliefs and expectations of the company\xe2\x80\x99s management and are subject to significant risks and uncertainties.
  • There can be no guarantees with respect to whether the proposed spinoff will be completed on the proposed timetable or at all.

Organon Announces Pricing of Senior Notes Offering

Retrieved on: 
金曜日, 4月 9, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Contemporary philosophy, Organon, Term logic, Schering-Plough, Oss, Organon, Merck

Organon Finance 1 LLC, a subsidiary of Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Organon Finance 1 LLC has priced its previously announced offering of 1,250,000,000 aggregate principal amount of 2.875% senior secured notes due 2028 (the euro secured notes), $2,100,000,000 aggregate principal amount of 4.125% senior secured notes due 2028 (the U.S. dollar secured notes) and $2,000,000,000 aggregate principal amount of 5.125% senior unsecured notes due 2031 (the unsecured notes and together with the euro secured notes and U.S. dollar secured notes, the notes), in connection with the previously announced spinoff of Organon & Co. (Organon) from Merck.

Key Points: 
  • Organon Finance 1 LLC, a subsidiary of Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Organon Finance 1 LLC has priced its previously announced offering of 1,250,000,000 aggregate principal amount of 2.875% senior secured notes due 2028 (the euro secured notes), $2,100,000,000 aggregate principal amount of 4.125% senior secured notes due 2028 (the U.S. dollar secured notes) and $2,000,000,000 aggregate principal amount of 5.125% senior unsecured notes due 2031 (the unsecured notes and together with the euro secured notes and U.S. dollar secured notes, the notes), in connection with the previously announced spinoff of Organon & Co. (Organon) from Merck.
  • As part of the spinoff, the notes will be assumed by Organon, and a Dutch private limited company and wholly owned subsidiary of Organon which will act as co-issuer of the notes.
  • Organon intends to use the net proceeds from the notes offering, together with available cash on its balance sheet and borrowings under senior secured credit facilities which Organon anticipates entering into, to repay one or more intercompany loans or notes owed by Organon to a Merck affiliate and to pay fees and expenses related to the spinoff.
  • Prior to the Effective Date, each series of notes will be senior secured obligations solely of the Organon Finance 1 LLC, and will not be guaranteed by Organon or any of its subsidiaries.

Organon Announces Proposed Senior Notes Offering

Retrieved on: 
火曜日, 4月 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Organon, Term logic, Contemporary philosophy, Schering-Plough, Oss, Organon, Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Organon Finance 1 LLC plans to offer, subject to market conditions, euro-denominated senior secured notes due 2028, U.S. dollar-denominated senior secured notes due 2028 and U.S. dollar-denominated senior unsecured notes due 2031 (collectively, the notes), in connection with the previously announced spinoff of Organon & Co. (Organon) from Merck.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Organon Finance 1 LLC plans to offer, subject to market conditions, euro-denominated senior secured notes due 2028, U.S. dollar-denominated senior secured notes due 2028 and U.S. dollar-denominated senior unsecured notes due 2031 (collectively, the notes), in connection with the previously announced spinoff of Organon & Co. (Organon) from Merck.
  • As part of the spinoff, the notes will be assumed by Organon and a Dutch private limited company and wholly owned subsidiary of Organon which will act as co-issuer of the notes.
  • Organon intends to use the net proceeds from the notes offering, together with available cash on its balance sheet and borrowings under senior secured credit facilities which Organon anticipates entering into, to repay one or more intercompany loans or notes owed by Organon to a Merck affiliate and to pay fees and expenses related to the spinoff.
  • The proceeds of the notes offering will be held in escrow until satisfaction of the conditions precedent to the spinoff and certain other escrow release conditions.

Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon

Retrieved on: 
火曜日, 3月 30, 2021
Biotechnology, General Health, Medical devices, Health, Pharmaceutical, Merck, Schering-Plough, Oss, Organon International, Merck & Co., Alydia Health, Organon, Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health.
  • Alydia Health is thrilled to join Organon as we hold a similar vision to bring technology and therapeutic solutions to market that can improve outcomes for women in need across the globe, said Rob Binney, chief executive officer, Alydia Health.
  • For more information, visit https://www.alydiahealth.com/ and follow the company on Twitter at @AlydiaHealth and on LinkedIn at @Alydia Health .
  • Organon will be a global healthcare company formed through a spinoff from Merck to focus on improving the health of women throughout their lives.